-
I upgraded my non-critical home laptop to Maverics and didn't have any issues yet. I don't use MacPorts however.. -
Because on my heavy reliance on MacPorts, I'm waiting for verification that MacPorts works with Mavericks. (I have not checked since Friday).Leave a comment:
-
OSX Mavericks
Hey guys,
Has anyone updated any of their Macs that they use for bioinformatics to Mavericks yet? We have a Mac Pro running 10.6.8 that we use for the heavy data analysis that we don't do on our linux clusters, as well as some iMacs that we use for lighter analyses and I'm considering whether or not it's worth it to upgrade them. The AppNap and compressed memory features in particular seem like they could give those systems a boost and help extend their usable life span.
Given that the upgrade is free, it's very tempting to just go ahead and try it, but my concern is that there will be unknown issues with some of the programs that we rely on for our analyses. Figure it was worth checking to see if others have upgraded yet and what their impressions were before I try it for myself.
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Leave a comment: